We present the case of a 45-year-old female patient who harbored two synchronous primary malignant neoplasms-an anaplastic oligodendroglioma of the right frontal lobe and a squamous cell carcinoma of the tongue. Both neoplasms were in advanced stage and carried a dismal prognosis. To the best of our knowledge, this is the first documentation in the english literature of such a presentation. The purpose of this article is to alert clinicians to this possibility and to outline the management approach in a different manner in patients presenting with multiple primary neoplasms.
INTRODUCTION
Two or more abnormal growths of tissue occurring simultaneously and presumed to be of separate origin are known as multiple primary neoplasms. Histologically, they could be the same or different, and the neoplasms may be found in the same or different sites. These lesions are classified into two groups: [1] synchronous -in which both the lesions appear at the same time or within 2 months and [2] metachronous -where the malignancies develop in sequence (more than 2 months apart). [1] Treatment strategies in cases of double malignancy generally involve treating the malignancy that is more advanced first. Sometimes, both malignancies may be treated simultaneously, if the therapeutic option is the same for both. Metachronous primary malignancies are becoming increasingly more common because of the increase in the number of elderly patients and improvements in diagnostic techniques. However, synchronous primary malignancies are still unusual. Data regarding treatment and outcome in such cases is sparse. The prognosis of synchronous tumors is significantly poorer when compared to malignancies of a metachronous nature, although there are some encouraging individual results. Only early implementation of aggressive treatment methods for second primaries is successful in terms of improving survival. [2] This case is being reported because of the extremely rare nature of the presentation. Awareness of this possibility is of utmost importance for formulating standard management.
CASE REPORT
A 45-year-old female presented in the neurosurgery outpatient department with history of right-sided headache and a single episode of generalized tonicclonic seizure. On general physical examination she was afebrile, had mild pallor, and had a Karnofsky performance status of 90%. Central nervous system examination revealed normal higher mental functions, normal motor/sensory system, no neck rigidity, and all cranial nerves were intact. Magnetic resonance imaging of brain revealed a large illdefined, irregular, diffusely infiltrating right frontal space-occupying lesion, with associated cystic component. The lesion showed extension up to the genu of the corpus callosum and the left frontal lobe, with perilesional edema extending up to the left parietal lobe [ Figure 1 ]. The patient underwent right frontal craniotomy and gross total resection of the lesion. The postoperative period was uneventful and she was put on anticonvulsant prophylaxis. Histopathology of the postoperative specimen revealed anaplastic oligodendroglioma [ Figure 2 ]. She was referred to our department for adjuvant radiotherapy (RT). After initial workup, the patient was planned for external beam radiotherapy as per department protocol. A total of 59.4 Gy was delivered to the gross disease in conventional fractionation by parallel opposed lateral portals by shrinking field technique using a telecobalt unit. After a few fractions of RT, the patient complained of pain in the left side of the tongue and referred pain in the left ear. CT scan of the head and neck region showed a heterogeneously enhancing soft tissue lesion involving most of the oral tongue, with extension to the base of the tongue and the left tonsillar fossa [ Figure 3] . There was associated level I and level II cervical lymphadenopathy, measuring 3.8 × 3.1 cm and 1.7 × 1.6 cm, respectively. She was advised biopsy from the ulcer and this revealed moderately differentiated squamous cell carcinoma [ Figure 4 ]. After completion of RT to the brain, she was lost to follow-up. When contacted over the phone, she reported in the outpatient department with advanced disease tongue. Considering her present performance status and disease stage, she was put on palliative RT to tongue and neck nodes. At her last follow-up, she had no neurological deficit clinically and the tongue primary showed partial response.
DISCUSSION
In 1889, Billroth published the first report of multiple primary malignancies. [3] Moertel, in his study of 37,580 cases of malignant disease, reported multiple primary malignant tumors in 10.6% of autopsy cases and 4.6% of surgical cases. [4] Willis considered that the multicentric origin of malignant neoplasia was the result of carcinogenic stimulus on a common tissue with a common cancer predisposition or susceptibility, with neoplasia commencing initially where the stimulus was maximum and occuring secondarily in a different part of the same tissue at a later date. [5] Warren and Gates [6] proposed the following criteria for diagnosis of multiple primary malignancies:
• Each tumor must give a definite picture of malignancy • Each must be distinct • The probability that one was a metastatic lesion from the other must be excluded.
Lund [7] classified multiple malignancies as: There have been several case reports in literature. One case reported from Japan had synchronous adenocarcinoma of lung and malignant astrocytoma of brain. [8] Hirota et al. reported carcinoma tongue as a second malignancy 2 years after cessation of chemotherapy in a 15-year-old girl treated for osteosarcoma. [9] Malkin et al. investigated the possibility that p53 mutations in the germline are associated with second primary cancers that arise in children and young adults who would not be considered as belonging to Li-Fraumeni families.
[10] Kohmura et al. found that the overexpression of cyclin D1 and p53 proteins was highly correlated with the development of multiple primary malignant neoplasms. [11] The PIK3CA gene is located on chromosome 3q26.32 and encodes for the catalytic subunit p110 alpha of class IA PI3K. Recently, high frequencies of somatic mutations in the PIK3CA gene have been reported in several human cancer types, including colon, head and neck, brain, stomach, breast, and ovary. [12] With synchronous tumors, a mean survival time of 18 months and a 5-year survival rate of 11.9% have been found. Where clinically appropriate, an aggressive treatment strategy should be employed as this approach yields the most favorable results, with 5-year survival rates of 66.8% and 35.9% for index tumors and second primary malignancies, respectively. [2] Aggarwal et al. [13] reported two cases of synchronous double malignancies: one of carcinoma cervix with carcinoma breast and another of frontoparietal astrocytoma and carcinoma parotid. They concluded that synchronous double malignancy can be treated successfully.
CONCLUSION
Sophisticated genetic, histopathologic, epidemiologic, and statistical approaches need to be used to improve our knowledge of the rate and patterns of occurrence of multiple cancers. Education of the patients, awareness of the clinicians, regular examinations of patients, and the use of screening procedures are important steps for the prophylaxis of multiple primary tumors and may lead to a better outcome for the individual patient. In our patient, the prognosis of both tumors was poor and early implementation of aggressive treatment could have improved the results and contributed to better quality of life. When a metachronous tumor is found after treatment of the first, the clinician should not assume that the latter is a metastasis but, rather, should explore the possibility of it being a second, potentially curable, primary. It is imperative, therefore that the cancer patient should be under continuous surveillance till the end of life even if he/ she is apparently 'cured.'
